12,372 trials
Influenza
Primary: Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events. — 22; 5; 2; 0 Participants
Active, Symptomatic Blepharitis
Primary: Number of Participants in the ITT Population With a Reduction in the Day 1 (Baseline) Total Clinical Signs and Symptom Score by at Least 2 Units at Day 15 With No…
Sedation
Primary: Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During…
Arthritis · Osteoarthritis
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)…
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Prostate Cancer
Primary: Number of Subjects Achieving a Reduction of 25% or Greater in Percent Volume of the Rectum Receiving at Least 70 Gy Measured From CT Scans Acquired Pre and Post SpaceOAR…
Polymorphic Light Eruption
Primary: Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale — 0.25; 0.47 score on a scale
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event — 9.0; 11.3; 54.0; 42.3 Percentage of Participants — p=0.175
Herpes Zoster
Primary: Percentage of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in Co-Ad Group — 99.1 Percentage of subjects
Coronavirus · Acute Respiratory Infection · SARS-CoV Infection
Primary: COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization) — 6; 6 score on a scale
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Covid-19
Primary: Number of Participants Who Achieved Clinical Response by Day 15 — 7; 7; 4 Participants
Breast Cancer
Primary: Percentage of Participants With Disease-free Survival (DFS) — 78.97; 83.37 Percentage of participants — p=0.175
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16 — 62.9; 3.8 percentage of participants — p=<0.001
Juvenile Dermatomyositis
Primary: Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by >…